PARP1 and cancer: These data strongly suggest that the enhancement of the PARP1 trapping activity of veliparib, without potentiation of the PARylation inhibition activity, ultimately leads to an increase of the cytotoxicity of this inhibitor in BRCA1m cancer cells.